12/21/2012

The FDA asked state officials to help close gaps in the oversight of compounded drugs following the meningitis outbreak tied to tainted drugs from the New England Compounding Center. The agency's authority should be clear when monitoring the operations of compounding pharmacies, and health officials should act to prevent issues that risk public safety, FDA Commissioner Dr. Margaret Hamburg said. Furthermore, Hamburg said, better training is needed for state regulators, and states and the FDA need to improve sharing of information.

Related Summaries